High-affinity CRF1 receptor antagonist NBI-34041: preclinical and clinical data suggest safety and efficacy in attenuating elevated stress response.
about
Evidence for the role of corticotropin-releasing factor in major depressive disorderEmerging targets for antidepressant therapiesNovel targets for antidepressant therapiesTherapeutic utility of non-peptidic CRF1 receptor antagonists in anxiety, depression, and stress-related disorders: evidence from animal modelsPersistent anxiolytic affects after chronic administration of the CRF₁ receptor antagonist R121919 in rats.Single-nucleotide polymorphisms in corticotropin releasing hormone receptor 1 gene (CRHR1) are associated with quantitative trait of event-related potential and alcohol dependenceProgress in corticotropin-releasing factor-1 antagonist development.Neuroendocrine control of the gut during stress: corticotropin-releasing factor signaling pathways in the spotlight.Deducing corticotropin-releasing hormone receptor type 1 signaling networks from gene expression data by usage of genetic algorithms and graphical Gaussian modelsCorticotropin releasing factor receptor antagonists for major depressive disorder.Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder.Interaction of stress, corticotropin-releasing factor, arginine vasopressin and behaviour.Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning?Cortisol response to individualised graded insulin infusions: a reproducible biomarker for CNS compounds inhibiting HPA activation.Role of Corticotropin-releasing Factor Signaling in Stress-related Alterations of Colonic Motility and Hyperalgesia.The newly developed CRF1-receptor antagonists, NGD 98-2 and NGD 9002, suppress acute stress-induced stimulation of colonic motor function and visceral hypersensitivity in rats.Corticotropin releasing hormone and imaging, rethinking the stress axis.Corticotropin releasing factor signaling in colon and ileum: regulation by stress and pathophysiological implicationsA role for corticotropin-releasing factor in functional gastrointestinal disorders.MPZP: a novel small molecule corticotropin-releasing factor type 1 receptor (CRF1) antagonist.Cognitive disruptions in stress-related psychiatric disorders: A role for corticotropin releasing factor (CRF).Making a bad thing worse: adverse effects of stress on drug addiction.Combined Pharmacotherapy and Cognitive-Behavioral Therapy for Anxiety Disorders: Medication Effects, Glucocorticoids, and Attenuated Treatment Outcomes.Single-Dose Study of a Corticotropin-Releasing Factor Receptor-1 Antagonist in Women With 21-Hydroxylase Deficiency.Sex differences in the locus coeruleus-norepinephrine system and its regulation by stress.Targeting brain angiotensin and corticotrophin-releasing hormone systems interaction for the treatment of mood and alcohol use disorders.Corticolimbic transcriptome changes are state-dependent and region-specific in a rodent model of depression and of antidepressant reversalCortagine, a CRF1 agonist, induces stresslike alterations of colonic function and visceral hypersensitivity in rodents primarily through peripheral pathways.Emerging drugs for major depressive disorder.Addiction and corticotropin-releasing hormone type 1 receptor antagonist medications.Corticotropin-releasing factor 1 receptor antagonists: a patent review.Biocatalytic synthesis of chiral alcohols and amino acids for development of pharmaceuticals.Effects of fluoxetine on CRF and CRF1 expression in rats exposed to the learned helplessness paradigm.Conditional mouse mutants highlight mechanisms of corticotropin-releasing hormone effects on stress-coping behavior.Preliminary evidence of anxiolytic effects of the CRF(1) receptor antagonist R317573 in the 7.5% CO(2) proof-of-concept experimental model of human anxiety.Clinical safety and hypothalamic-pituitary-adrenal axis effects of the arginine vasopressin type 1B receptor antagonist ABT-436.Structure and Modeling of GPCRs: Implications for Drug Discovery
P2860
Q26798878-C0221888-03BD-45AD-BFAE-B3DB4C4B9340Q28247614-12078E97-43C7-44D6-9CCF-327831CCC77FQ28648254-E21F26FB-C95F-4B49-8F0E-11EF0B9C01C9Q30466695-24F0CEFD-126F-4790-8E9A-1CEEC997ED6EQ30467178-6CE651F0-F51F-4DFF-82F3-416C400CED1EQ30471884-9265EED7-BB19-4076-8886-123D28B53D2AQ30475627-CF092E41-6CC2-420B-9E44-F1870D1338DDQ30484216-8C0ACA6C-27A6-4B2B-80AC-A29443C98429Q33751836-9C92A2E9-9F5B-4F1C-8331-60E905B03212Q33843656-D644CB92-9623-4C98-961B-843B54E422C7Q34114364-324976BB-B665-4302-BF59-FB0CD61EF781Q34225879-846C22D7-9C24-4D26-8101-38B663E4C0A9Q34275762-D125256A-F884-4730-9884-B497E0D8884FQ34457448-852518DD-468B-4314-89EB-6E49F4B9CC40Q34882307-F9CF5E0F-03F8-4CA1-924A-4C4E894F621EQ34989237-4B411062-B4BE-442E-B5C4-BA1F41505536Q35181618-26D979A4-B4BA-4E4A-B3BB-04457A2AC1A6Q35809342-58877D6B-C0F5-44DF-903B-9F8101E90AD4Q35809350-C7DAC3C2-DC4B-4266-8164-BCCA68527CBFQ35869282-0A178F36-7673-4199-8C2E-2EC7979284B1Q36161776-C469EC99-4A6E-4E95-A47F-90AA74AEF763Q36407029-72E60821-69CF-41D7-B364-B9528A2C2252Q36551965-B172532D-5FFB-43BA-8ED5-CA104CDAC71EQ36716079-9BFEFE8A-D475-4B37-A505-245C64563285Q36923878-D14B56CC-3D86-48DD-A588-748956A38698Q37151967-865BE772-6532-4E06-8892-71828C2448E7Q37159953-9F383677-DE41-4E9E-AFD6-3A6DB7F9328FQ37264524-07AC3F8F-FC52-4B0B-9035-742389B593DBQ37564562-D6043E73-392F-47CF-93D1-3C0F405BACBAQ38080576-0C1A59A9-CF15-407E-8F58-0253089D6A26Q38103911-1C169643-8375-4DCC-A178-6C10760009D5Q39871919-8ADF64EE-66A6-43A5-BDAF-E8DA8AA8FC4AQ44518261-E04803FA-987D-4F88-8FA3-9EE927A6E54FQ46599000-369A9CEF-5BE4-4596-B54C-DDEF1E07E6CAQ48874157-E3FBBE0F-130D-42D0-9908-BD9E7124A693Q52148833-B6E97381-20ED-4FD0-B647-58C8EE366BB6Q57015852-BF73974F-758A-40FD-B2F6-79AFCAAA33DB
P2860
High-affinity CRF1 receptor antagonist NBI-34041: preclinical and clinical data suggest safety and efficacy in attenuating elevated stress response.
description
2007 nî lūn-bûn
@nan
2007 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
High-affinity CRF1 receptor an ...... ting elevated stress response.
@ast
High-affinity CRF1 receptor an ...... ting elevated stress response.
@en
type
label
High-affinity CRF1 receptor an ...... ting elevated stress response.
@ast
High-affinity CRF1 receptor an ...... ting elevated stress response.
@en
prefLabel
High-affinity CRF1 receptor an ...... ting elevated stress response.
@ast
High-affinity CRF1 receptor an ...... ting elevated stress response.
@en
P2093
P2860
P50
P356
P1476
High-affinity CRF1 receptor an ...... ting elevated stress response.
@en
P2093
Alan C Foster
Dimitri E Grigoriadis
Heike E Künzel
Susan M Learned-Coughlin
Ulrich S Zimmermann
P2860
P2888
P304
P356
10.1038/SJ.NPP.1301328
P407
P577
2007-02-07T00:00:00Z
P5875
P6179
1042483283